3D Bioprinting Market Summary

The global 3D bioprinting market size was valued at USD 2.3 billion in 2023 and is projected to reach USD 5.3 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030. The market expansion is primarily driven by the persistent shortage of organ donors and the rising elderly population suffering from chronic respiratory conditions. These demographic and medical challenges continue to heighten the demand for advanced bioprinting solutions capable of producing functional tissues and organ structures for research, therapeutic, and regenerative purposes.

Rising R&D investment, continuous technological advancements, and the growing global burden of chronic diseases are additional factors significantly influencing market growth. The 3D printing community demonstrated its capability during the COVID-19 crisis by contributing to the production of essential medical devices and components at a time when global supply chains were severely strained. As the pandemic pushed even well-equipped healthcare systems to their limits, 3D bioprinting communities across the world stepped forward with innovative solutions, helping reduce pressure on governments and ensuring improved accessibility to critical healthcare equipment.

Key Market Trends & Insights

• North America captured a revenue share of 30.2% in 2023, benefiting from strong research infrastructure, high healthcare spending, and widespread adoption of bioprinting technologies across academic and commercial sectors.
• Asia Pacific accounted for a revenue share of 27.2% in 2023, supported by expanding biotech investments, growing healthcare modernization, and increasing government initiatives aimed at enhancing regenerative medicine capabilities.
• By technology, the inkjet-based segment accounted for the largest revenue share of 35.87% in 2023, reflecting its precision, cost efficiency, and suitability for printing complex biological materials with high cell viability.
• By application type, the medical segment held the largest market share of 38.5% in 2023 and is anticipated to grow at a CAGR of around 15.0% over the forecast period, driven by the rising need for tissue engineering, personalized medicine, drug testing, and organ transplantation substitutes.

Order a free sample PDF of the 3D Bioprinting Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 2.3 Billion
• 2030 Projected Market Size: USD 5.3 Billion
• CAGR (2024-2030): 12.5%
• North America: Largest market in 2023

Key Companies & Market Share Insights

Key companies are focusing on R&D to develop technologically advanced applications to gain a competitive edge. For instance, in November 2019, CELLINK’s developed the most advanced 3D bioprinting device, Bio X6, as well as Lumen X which produces vascular structures. Also, Fluicell Sweden-based company has launched a high-resolution bioprinting technology in both 3D and 2D forms, which is named Biopixlar.

Companies are engaging in mergers, partnerships, and acquisitions, aiming to strengthen their manufacturing capacities, and application portfolio, and provide competitive differentiation. For instance, in November 2019, BASF GmbH announced the acquisition of Sculpteo which is a 3D printing service provider. This acquisition is expected to aid BASF GmbH in the market and develop new industrial 3D printing materials more quickly.

Key Players

• EnvisionTEC, Inc.
• Organovo Holdings, Inc.
• Inventia Life Science PTY LTD
• Poietis
• Vivax Bio, LLC
• Allevi
• Cyfuse Biomedical K.K.
• 3D Bioprinting Solutions
• Cellink Global
• Regemat 3D S.L.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The 3D bioprinting market is positioned for strong long-term growth as global healthcare systems increasingly adopt advanced biofabrication technologies to address critical unmet medical needs. With rising investment, expanding research collaborations, and broader clinical applications, the technology continues to gain momentum across regenerative medicine, pharmaceutical testing, and personalized treatment development. The accelerated innovation observed during the COVID-19 pandemic demonstrated the ability of bioprinting communities to respond quickly to healthcare challenges. As advancements in materials, printing precision, and regulatory support continue to improve, 3D bioprinting is expected to play an increasingly essential role in shaping the future of medical science.